[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"restless-leg-syndrome-rls\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:restless-leg-syndrome-rls":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,9,0,[8,46,73,95,119,145,169,200,226],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":28,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100606734","the-effect-of-spinal-cord-stimulators-on-restless-leg-syndrome-100606734",false,"NCT07179406","The Effect of Spinal Cord Stimulators on Restless Leg Syndrome","Inclusion Criteria:\n\n* Has Restless Leg Syndrome\n* No major changes in RLS medications in past 4 weeks\n* Willing and able to comply with study protocol\n* Healthy Controls - No RLS diagnosis\n* Ability to provide informed consent\n\nExclusion Criteria:\n\n* Any mental or physical limitation that would prevent completing any of the studies\n* Currently using another device to treat RLS\n* Unable or unwilling to comply with study protocols\n* Other medical condition that would put the subject at risk as determined by the investigator\n* Pregnant, breastfeeding, or trying to become pregnant\n* Currently participating or planning to participate in any other investigational clinical evaluation during the study period that may, in the opinion of the investigator, affect RLS\n* One or more of the following diseases: spinal cord injury, severe peripheral neuropathy or radiculopathy, severe psychiatric or cognitive disorder that may interfere with participation of the study, history of drug or alcohol abuse within the past year, epilepsy or seizure disorder, current active or chronic infection other than the common cold, malignancy within the past 5 years (not including basal cell or squamous cell skin cancer), severe movement disorder (i.e. Parkinson's disease), deep vein thrombosis, or multiple sclerosis.",true,"ALL","18 Years",{"count":19,"type":20},50,"ESTIMATED","INTERVENTIONAL",[23],"NA","This study aims to evaluate neurophysiological responses and symptom changes in individuals with Restless Legs Syndrome (RLS) and\u002For chronic pain. Participants will undergo standard clinical assessments including EEG, EMG, h-reflex, SSEP, ERP, and TMS under varying SCS conditions.The study involves 4 arms. Arm 1 are individuals diagnosed with RLS and Healthy Controls. Arm 2 are individuals diagnosed with RLS and have an existing SCS. Arm 3 are individuals diagnosed with RLS and scheduled to receive a SCS. Arm 4 are individuals with chronic pain and have a SCS, but no diagnosis of RLS.",[26,27],"Restless Leg Syndrome (RLS)","Spinal Cord Stimulation (SCS)",[29,30,31,32],"SCS","Spinal Cord Stimulation","RLS","Restless Leg Syndrome","RECRUITING","2026-06-23",{"date":36,"type":37},"2026-06-26","ACTUAL",{"date":39,"type":37},"2025-08-04",{"date":41,"type":20},"2028-12-31",{"name":43,"class":44},"University of Alabama at Birmingham","OTHER",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":54,"targetDuration":4,"studyType":21,"phases":56,"briefSummary":57,"conditions":58,"keywords":59,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":72},"100636903","study-on-the-efficacy-of-spinal-cord-stimulation-in-patients-with-severe-refractory-primary-or-secondary-rls-100636903","NCT07571733","Study on the Efficacy of Spinal Cord Stimulation in Patients With Severe Refractory Primary or Secondary RLS","A Double-Blind, Randomized, Sham-Controlled, Crossover Study on the Efficacy of Burst Spinal Cord Stimulation in Patients With Severe Refractory Primary or Secondary RLS: the REST-SCS Study","REST-SCS","Inclusion Criteria:\n\n* Male and female (all sexes) aged 18 years or older, inclusive;\n* Diagnosis of primary or secondary RLS;\n* Severe to very severe RLS defined as IRLS-RS score \\> 20;\n* Duration of RSL symptoms ≥ 6 months;\n* Insufficient symptom control achieved by and\u002For intolerance to established mono- or combination therapy of standard pharmacological treatment incl. patients in augmentation;\n* Stable pharmacologic therapy for RLS for at least 1 month;\n* A stable pattern of neurological symptoms;\n* Patients who are legally competent and able to understand the nature, scope and aim of the clinical trial;\n* Signed informed subject consent form\n\nExclusion Criteria:\n\n* Known hypersensitivity or allergy to the materials of the device;\n* Concomitant use of psychoactive-drugs (e.g. benzodiazepines, antidepressants; wash-out period: at least 7 days or longer depending on half-life);\n* Co-morbid sleep disorders influencing sleep structure and nocturnal motor pattern (e.g. Narcolepsy, REM sleep behaviour disorder etc.);\n* Coagulopathy or oral anticoagulant therapy (except low-dose acetylsalicylic acid) in conditions that do not allow for a temporary discontinuation;\n* Active infection, systemic or localized;\n* Known immune deficiency;\n* Presence of spinal cord or peripheral nerve stimulators;\n* Any disease process or condition that may make the effect of the treatment difficult to evaluate (e.g. cancer with low life expectancy);\n* Severe psychiatric disorders (including substance abuse, major depression, and similar severe disorders known or suspected non-compliance) which could have a negative influence on successful treatment;\n* Inability to follow the procedures of the study, e.g. due to language problems, dementia, etc. of the participant;\n* Women who are pregnant or breast feeding;\n* Intention to become pregnant during the course of the study;",{"count":55,"type":20},15,[23],"A Double-Blind Randomized Controlled Crossover Study to compare the short-efficacy of Burst-SCS with Sham Stimulation, in patients with severe to very severe RLS refractory or intolerant to standard available treatments and\u002For patients in augmentation, with a two-period-alternating treatment design.",[26],[26,60,61],"Neurostimultor for Restless Leg Syndorme","Neurostimulator","NOT_YET_RECRUITING","2026-04-30",{"date":65,"type":37},"2026-05-06",{"date":67,"type":20},"2026-06-01",{"date":69,"type":20},"2029-02-14",{"name":71,"class":44},"Clinica ARS Medica",2,{"id":74,"slug":75,"hasResults":11,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":4,"eligibilityCriteria":79,"healthyVolunteers":11,"sex":16,"minAge":80,"maxAge":4,"enrollmentInfo":81,"targetDuration":4,"studyType":21,"phases":83,"briefSummary":84,"conditions":85,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":86,"lastUpdatePostDateStruct":87,"startDateStruct":89,"completionDateStruct":91,"leadSponsor":93,"locationsCount":72},"100582471","using-cannabis-to-treat-restless-legs-syndrome-100582471","NCT06863740","Using Cannabis to Treat Restless Legs Syndrome","Using Cannabis to Treat Restless Legs Syndrome: A Randomized Placebo Controlled Pilot Safety and Feasibility Trial","Inclusion Criteria:\n\n* ≥25 years of age\n* diagnosis of RLS based on the International RLS Study Group criteria\n* refractory RLS symptoms despite use of dopaminergic and\u002For alpha-2-delta ligand therapy\n* onset of RLS at least 6 months before screening\n\nExclusion Criteria:\n\n* sleep disordered breathing, or sleep disordered breathing that is not adequately controlled on therapy (apnea-hypopnea index of \\>15)\n* cannabis use within 4 weeks of study enrollment\n* known allergy to cannabis, cannabinoids or palm\u002Fcoconut oil\n* Currently pregnant or breast-feeding (a negative urine pregnancy test must be obtained for women of childbearing potential during pretreatment evaluation)\n* Active substance abuse\n* Ischemic heart disease with unstable angina or recent acute coronary syndrome in the last 3 months, uncontrolled arrhythmias, poorly controlled hypertension\n* Serious liver disease\n* History of schizophrenia or any other psychotic disorder","25 Years",{"count":82,"type":20},30,[23],"Restless Legs Syndrome (RLS) is a disorder that causes painful and uncomfortable sensations in the legs, and its symptoms have a significant impact on sleep and quality of life. Cannabis has been used by some RLS patients as a treatment due to its painkilling and drowsiness effects, however there has never been a clinical research trial investigating cannabis in patients with RLS. A controlled trial is needed to establish how safe and feasible cannabis is as a treatment for RLS. The investigators plan to randomize 30 participants with moderate-to-severe RLS to receive either cannabis or placebo for 8 weeks. The investigators will measure patients sleep quality and quality of life at baseline and 8-week follow-up. The investigators will also monitor patients for any adverse reactions to the study drug.",[26],"2026-04-22",{"date":88,"type":37},"2026-04-28",{"date":90,"type":37},"2025-07-25",{"date":92,"type":20},"2027-05",{"name":94,"class":44},"Sunnybrook Health Sciences Centre",{"id":96,"slug":97,"hasResults":11,"nctId":98,"briefTitle":99,"officialTitle":100,"acronym":4,"eligibilityCriteria":101,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":102,"enrollmentInfo":103,"targetDuration":4,"studyType":21,"phases":105,"briefSummary":107,"conditions":108,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":110,"lastUpdatePostDateStruct":111,"startDateStruct":113,"completionDateStruct":115,"leadSponsor":117,"locationsCount":45},"100627840","phase-1-novel-calcium-channel-modulators-in-rls-and-variants-efficacy--safety-100627840","NCT07453862","Novel Calcium Channel Modulators in RLS and Variants: Efficacy & Safety","Observation of Efficacy and Safety of Novel Calcium Channel Modulators in the Treatment of Restless Legs Syndrome and Its Variant Subtypes","Inclusion Criteria:\n\n* 1\\. Aged 18-75 years, regardless of gender.\n* 2\\. Meets the diagnostic criteria for typical Restless Legs Syndrome (RLS) (IRLSSG criteria) or variant RLS confirmed by a neurologist.\n* 3\\. Moderate to severe RLS (IRLS score ≥11).\n* 4\\. Able to understand and comply with the study protocol, and provides written informed consent.\n\nExclusion Criteria:\n\n* 1\\. Secondary RLS (e.g., iron deficiency anemia with serum ferritin \\\u003C30μg\u002FL, renal dysfunction with eGFR \\\u003C30ml\u002Fmin, pregnancy\u002Flactation, drug-induced RLS with unadjustable medications).\n* 2\\. Severe central nervous system diseases (e.g., status epilepticus, severe dementia, stroke within 3 months).\n* 3\\. Severe cardiovascular diseases (e.g., congestive heart failure, uncontrolled hypertension with SBP≥180mmHg or DBP≥110mmHg).\n* 4\\. Severe liver or kidney dysfunction (ALT\u002FAST \\>3×ULN, eGFR \\\u003C30mL\u002Fmin\u002F1.73m²).\n* 5\\. Active mental illnesses (e.g., schizophrenia, acute bipolar disorder).\n* 6\\. Hypersensitivity to Keligabalin Benzenesulfonic Acid or its excipients.\n* 7\\. Participation in other clinical trials within 1 month, inability to cooperate with follow-up, or history of substance abuse.\n* 8\\. Pregnancy or lactation.","75 Years",{"count":104,"type":20},20,[106],"PHASE1","The goal of this \\[study type: clinical trial\\] is to \\[primary purpose: evaluate the efficacy and safety of a novel calcium channel modulator in treating Restless Legs Syndrome (RLS) and its variant subtypes\\] in \\[describe participant population\u002Fprimary condition: adult patients aged 18-75 years with confirmed RLS or its variant subtypes, who meet the study's eligibility criteria\\]. The main question\\[s\\] it aims to answer \\[is\u002Fare\\]:\n\n* Does the novel calcium channel modulator improve RLS-related symptoms (assessed by the International Restless Legs Syndrome Study Group Rating Scale, IRLS) after the treatment period?\n* What is the safety profile (incidence of adverse events) of this calcium channel modulator in RLS patients?\n\nParticipants will \\[describe the main tasks participants will be asked to do, interventions they'll be given\\]:\n\n* Receive oral administration of the novel calcium channel modulator (40mg twice daily) for 12 consecutive weeks\n* Complete scheduled follow-up visits for symptom assessments, safety monitoring, and questionnaire completion",[26,109],"Variant Restless Legs Syndrome","2026-03-03",{"date":112,"type":37},"2026-03-06",{"date":114,"type":20},"2026-03-10",{"date":116,"type":20},"2027-08-31",{"name":118,"class":44},"Beijing Friendship Hospital",{"id":120,"slug":121,"hasResults":11,"nctId":122,"briefTitle":123,"officialTitle":124,"acronym":4,"eligibilityCriteria":125,"healthyVolunteers":11,"sex":16,"minAge":126,"maxAge":127,"enrollmentInfo":128,"targetDuration":4,"studyType":21,"phases":130,"briefSummary":131,"conditions":132,"keywords":4,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":136,"lastUpdatePostDateStruct":137,"startDateStruct":139,"completionDateStruct":141,"leadSponsor":143,"locationsCount":45},"100614225","effect-of-autogenic-training-on-hemodialysis-patients-100614225","NCT07276828","Effect of Autogenic Training on Hemodialysis Patients","Effect Of Autogenic Training On Restless Leg Syndrome And Sleep Disturbance In Hemodialysis","Inclusion Criteria\n\n* Age between 45 and 55 years.\n* Body Mass Index (BMI) between 25.0 and 29.9 kg\u002Fm².\n* Clinically and medically stable.\n* On hemodialysis for at least 6 months prior to enrollment.\n* Diagnosed with chronic kidney disease (CKD), defined by one or more of the following:\n\nEvidence of kidney damage (e.g., albuminuria), or\n\nDecreased kidney function with glomerular filtration rate (GFR) \\\u003C 60 mL\u002Fmin\u002F1.73 m² for ≥ 3 months, irrespective of clinical diagnosis.\n\n\\*Systolic blood pressure \\\u003C 140 mmHg, diastolic blood pressure \\\u003C 90 mmHg, and heart rate \\\u003C 80 bpm.\n\nExclusion Criteria\n\nUncontrolled pulmonary disease.\n\nSevere vascular complications (e.g., critical limb ischemia).\n\nUnstable angina.\n\nUncontrolled cardiac arrhythmia.\n\nDecompensated heart failure.\n\nCognitive impairment.\n\nParticipants who miss more than two weeks of the program or request termination.","45 Years","55 Years",{"count":129,"type":20},54,[23],"goal of this interventional study to investigate the effect of autogenic training on sleep disturbance , restless leg syndrome and fatigue on hemodialysis patient Is there any significant effect of autogenic training on restless leg syndrome, sleep disturbance and fatigue in patients with hemodialysis?\n\nThe intervention will include structured autogenic training sessions, and outcomes such as sleep quality and RLS severity and fatigue will be evaluated after 8 weeks of autogenic training on hemodialysis patients .",[133,26,134,135],"Hemodialysis Patient","Fatigue","Sleep Disturbance","2025-12-16",{"date":138,"type":37},"2025-12-22",{"date":140,"type":20},"2025-12-15",{"date":142,"type":20},"2027-05-15",{"name":144,"class":44},"Cairo University",{"id":146,"slug":147,"hasResults":11,"nctId":148,"briefTitle":149,"officialTitle":150,"acronym":4,"eligibilityCriteria":151,"healthyVolunteers":11,"sex":16,"minAge":152,"maxAge":153,"enrollmentInfo":154,"targetDuration":4,"studyType":21,"phases":156,"briefSummary":157,"conditions":158,"keywords":159,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":140,"lastUpdatePostDateStruct":161,"startDateStruct":163,"completionDateStruct":165,"leadSponsor":167,"locationsCount":4},"100616628","combined-effects-of-near-infrared-light-and-vibration-on-diabetic-patients-with-restless-leg-syndrome-100616628","NCT07308080","Combined Effects of Near-Infrared Light and Vibration on Diabetic Patients With Restless Leg Syndrome","Combined Effects of Near-Infrared Light and Vibration on Pain, Sleep Quality and Symptoms Severity in Diabetic Patients With Restless Leg Syndrome","Inclusion Criteria:\n\nPatients of age 50-65 years Both male and female patients with Type II diabetes Patients with a diagnosis of diabetes at least 6 months ago RLS (score of 11+ on the RLS scale) Patients meeting the four key RLS diagnosis criteria will be included in the study.\n\nCriterion is: Urge to move due to uncomfortable leg sensations, symptoms worsening at rest, symptoms relief with movement ,greater symptom severity in the evening or at night.\n\nWillingness to provide informed consent .\n\nExclusion Criteria:\n\nPatients using analgesics, psychiatric, or neurological medications. Patients with any malignancies, neurological, skeletal, or vascular disorders History of drug abuse. Ongoing RLS treatments (e.g. vibration therapy, massage). Severe cognitive impairment. Pregnancy or lactation. Conditions contraindicating NIR or vibration therapy","50 Years","65 Years",{"count":155,"type":20},42,[23],"This Randomized Clinical Trial, titled \"Combined Effects of Near-Infrared Light and Vibration on Pain, Sleep Quality and Symptom Severity in Diabetic Patients with Restless Leg Syndrome,\" aims to evaluate a non-pharmacological treatment for Restless Leg Syndrome (RLS) in diabetic patients. RLS is a neurological disorder causing an irresistible urge to move the legs, and its co-occurrence with diabetes significantly worsens symptoms, pain, and sleep quality. While both Near-Infrared (NIR) light therapy and vibration therapy have individually shown benefits, this study will investigate the potential synergistic effects of combining them. 42 diabetic patients with RLS (aged 50-65) will be randomly assigned to one of three groups for four weeks (3 sessions\u002Fweek): Group A (Vibration + Conventional Stretching), Group B (NIR Light + Conventional Stretching), and Group C (Combined Vibration and NIR Light + Conventional Stretching). Outcomes will be measured at baseline, 4 weeks, and 6 weeks using the International Restless Leg Syndrome Rating Scale (IRLS), the Pittsburgh Sleep Quality Index (PSQI), and the Numeric Pain Rating Scale (NPRS). This research explores the synergistic effects of near-infrared light and vibration therapy on Restless Leg Syndrome (RLS) symptoms in diabetic patients, aiming to alleviate symptoms, improve sleep quality, and enhance overall well-being.",[26],[160],"RLS, Diabetic patient, Near-Infrared Light, Vibration, Pain, Sleep Quality",{"date":162,"type":37},"2025-12-29",{"date":164,"type":20},"2025-12-14",{"date":166,"type":20},"2026-05",{"name":168,"class":44},"Lahore University of Biological and Applied Sciences",{"id":170,"slug":171,"hasResults":11,"nctId":172,"briefTitle":173,"officialTitle":174,"acronym":175,"eligibilityCriteria":176,"healthyVolunteers":11,"sex":177,"minAge":17,"maxAge":4,"enrollmentInfo":178,"targetDuration":4,"studyType":21,"phases":179,"briefSummary":180,"conditions":181,"keywords":185,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":191,"lastUpdatePostDateStruct":192,"startDateStruct":194,"completionDateStruct":196,"leadSponsor":198,"locationsCount":72},"100604062","peroneal-electrical-nerve-stimulation-in-pregnancy-for-restless-legs-syndrome-100604062","NCT07144631","Peroneal Electrical Nerve Stimulation in Pregnancy for Restless Legs Syndrome","PENS-P: Peroneal Electrical Nerve Stimulation in Pregnancy for Restless Legs Syndrome (RLS)","PENS-P","Inclusion Criteria:\n\n* Age ≥18 years\n* Pregnant individuals between 21 and 26 weeks' gestation at enrollment\n* Singleton pregnancy without known fetal anomalies\n* Confirmed clinical diagnosis of Restless Legs Syndrome (RLS) according to International Restless Legs Syndrome Study Group (IRLSSG) criteria, confirmed by a sleep medicine specialist to exclude RLS mimics\n* Able and willing to provide informed consent\n* Able and willing to comply with study procedures, including device usage, questionnaires, adherence diaries, and follow-up assessments up to 3 months postpartum\n\nExclusion Criteria:\n\nPregnancy-related:\n\n* History of preterm labor\n* Known fetal anomalies identified prior to enrollment\n\nNeurological and neuromuscular disorders:\n\n* Pre-existing neuromuscular disorders affecting balance or gait\n* Severe peripheral neuropathy involving the lower legs\n* Epilepsy or history of seizures\n\nCardiovascular and circulatory conditions:\n\n* History of deep vein thrombosis (DVT)\n* Circulatory conditions contraindicating peroneal nerve stimulation (PNS) device use\n\nDermatological conditions:\n\n* Skin conditions at device application sites\n* Known allergy to device materials\n\nOther sleep disorders:\n\n• Inadequately treated severe primary sleep disorders other than RLS (e.g., untreated severe sleep apnea, severe insomnia unrelated to RLS)\n\nDevice and treatment experience exclusions (based on RESTFUL trial criteria):\n\n* Prior use of the study device or any neurostimulation device for RLS treatment\n* Presence of active medical implants (e.g., pacemakers, spinal cord stimulators)\n\nOther medical conditions:\n\n* Participants undergoing dialysis treatment\n* Severe psychiatric conditions (e.g., bipolar disorder, psychosis, severe anxiety or depression) that may interfere with adherence or accurate symptom reporting\n* Any condition deemed by investigators to pose safety risks or impede participation\n\nOther exclusions:\n\n* Unable or unwilling to operate the device safely and independently\n* Unable to participate reliably in follow-up assessments or complete self-reported diaries","FEMALE",{"count":55,"type":20},[23],"The goal of this study is to evaluate whether peroneal electrical nerve stimulation (PNS) using the TOMAC™ device is a feasible, acceptable, and safe non-pharmacologic intervention for managing Restless Legs Syndrome (RLS) during pregnancy. This pilot study will also collect preliminary information on symptom relief, sleep quality, and maternal-fetal safety associated with device use.\n\nThe main questions the study aims to answer are:\n\nIs TOMAC™ PNS a feasible and acceptable intervention for RLS in pregnant individuals? Are there any maternal, fetal, or neonatal safety concerns with PNS use during pregnancy? What are the patterns of adherence, tolerance, and usability of the TOMAC™ device in this population?\n\nParticipants will:\n\nUse a non-invasive TOMAC™ peroneal nerve stimulator during 30-minute sessions as needed, for 8 weeks.\n\nComplete questionnaires assessing feasibility, acceptability, symptom severity, and sleep quality (including AIM, IAM, FIM, IRLS, PGI-I, PSQI, ESS, FOSQ, and MOS-II).\n\nWear an actigraphy monitor to collect objective sleep data at baseline and at 4 weeks.\n\nAttend scheduled follow-up visits and phone check-ins for maternal vital signs, uterine contraction and fetal monitoring, and neonatal outcome assessment.\n\nThis is a prospective, open-label, single-arm pilot study enrolling 15 pregnant participants between 21 and 26 weeks' gestation. Findings will provide the first dataset on the feasibility, acceptability, and safety of TOMAC™ PNS in pregnancy and inform the design of a future randomized controlled trial.",[182,26,183,184],"Restless Leg Disorder","Pregnancy","Sleep Disorder (Disorder)",[186,183,187,188,189,190],"Restless Legs Syndrome","Sleep Disorders in Pregnancy","Maternal Sleep Health","Peroneal Nerve Stimulation","Neuromodulation","2025-11-10",{"date":193,"type":37},"2025-11-12",{"date":195,"type":37},"2025-10-15",{"date":197,"type":20},"2026-10-31",{"name":199,"class":44},"Rhode Island Hospital",{"id":201,"slug":202,"hasResults":11,"nctId":203,"briefTitle":204,"officialTitle":205,"acronym":206,"eligibilityCriteria":207,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":208,"enrollmentInfo":209,"targetDuration":4,"studyType":210,"phases":4,"briefSummary":211,"conditions":212,"keywords":213,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":216,"lastUpdatePostDateStruct":217,"startDateStruct":219,"completionDateStruct":221,"leadSponsor":223,"locationsCount":45},"100571940","observe-change-in-nasal-swab-drd2-gene-expression-in-restless-legs-syndrome-rls-patients-on-prolonged-dopamine-agonist-treatment-100571940","NCT06726785","Observe Change in Nasal Swab DRD2 Gene Expression in Restless Legs Syndrome (RLS) Patients on Prolonged Dopamine Agonist Treatment","Gene Expression Changes on Extended Use of Dopamine Agonists in Restless Legs Syndrome (RLS)","RLS-DRD2gene","Inclusion Criteria:\n\n* Able to provide Informed Consent\n* Clinical diagnosis of Restless Legs Syndrome (RLS)\n* On-going Treatment with a dopamine agonist\n\nExclusion Criteria:\n\n\\* Use of any medication that might affect nasal epithelial cell collection with a nasal swab","60 Years",{"count":19,"type":20},"OBSERVATIONAL","The study aims to observe changes in dopaminergic genes expression in peripheral tissue upon prolonged dopamine agonist treatment on patients with Restless Legs Syndrome (RLS). Similar studies in Parkinson's disease have shown changes in alpha-synuclein expression, which might offer insights into the dopaminergic gene regulation seen in RLS. The dopamine agonist drugs to be included in this study are: Pramipexole (Mirapex), Ropinirole (Requip), Rotigotine (Neupro), Apomorphine (Apokyn), Bromocriptine (Parlodel). Specifically, the study will collect nasal swabs of participants partitioned into two groups, those who have not used a dopamine agonist or been on a dopamine agonist for less than 1 month compared to those who have been on the medication for 6 or more months. This research could provide insight into changes in dopaminergic gene expression associated with Augmentation Syndrome (AS) which occurs after long term dopamine agonist treatment in RLS patients.",[26],[214,31,215],"restless leg syndrome","neurological","2025-09-09",{"date":218,"type":37},"2025-09-11",{"date":220,"type":37},"2025-07-01",{"date":222,"type":20},"2026-02-27",{"name":224,"class":225},"HBC Immunology Inc","INDUSTRY",{"id":227,"slug":228,"hasResults":11,"nctId":229,"briefTitle":230,"officialTitle":230,"acronym":4,"eligibilityCriteria":231,"healthyVolunteers":11,"sex":16,"minAge":208,"maxAge":4,"enrollmentInfo":232,"targetDuration":4,"studyType":21,"phases":234,"briefSummary":235,"conditions":236,"keywords":239,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":242,"lastUpdatePostDateStruct":243,"startDateStruct":245,"completionDateStruct":247,"leadSponsor":249,"locationsCount":45},"100573550","effects-of-pnf-stretching-vs-conventional-physical-therapy-on-the-symptoms-of-restless-leg-syndrome-in-elderly-population-100573550","NCT06747741","Effects of PNF Stretching vs Conventional Physical Therapy on the Symptoms of Restless Leg Syndrome in Elderly Population.","Inclusion Criteria:\n\n* Age 60 and above.\n* Male \\& Females both.\n* must fulfill the diagnostic criteria of primary RLS.\n\nExclusion Criteria:\n\n* A history or underlying disease that would contribute to the symptoms of RLS.",{"count":233,"type":20},24,[23],"Restless leg Syndrome (RLS) is a common condition in the elderly population,characterized byan uncontrollable urge to move the leg,often occuring in the evening or at night,which can significantly disturb sleep and daily activities(ADL).\n\nAlthough various type of stretchings found to be effective on the symptoms of RLS,no study has specifically compared the effects of Proprioceptive Neuromuscular Facilitation stretching technique versus conventional physical therapy on the symptoms of RLS and related sleep disturbances.This study aims to fill this gap by evaluating the effectiveness of PNF stretching compared to conventional physical therapy,on the symptoms of RLS in elderly population.",[237,26,238,135],"Elderly","Proprioceptive Neuromuscular Facilitation",[237,32,135,240,241],"PNF stretching","Proprioceptive neuromuscular facilitation","2024-12-18",{"date":244,"type":37},"2024-12-24",{"date":246,"type":37},"2024-06-20",{"date":248,"type":20},"2024-12-20",{"name":250,"class":44},"Foundation University Islamabad"]